Nearly two-thirds of Canadians oppose longer patents for brand-name drugs under a
proposed trade deal with the European Union, according to a poll commissioned by the …

Europe that grants two more years of patent protection to the manufacturers of brand-name
pharmaceuticals, a provision that even the federal government acknowledges will likely …

This paper was prepared for a course on Canadian health policy. Its purpose is to expose
the harmful ramifications of international trade agreements on the pharmaceutical market in …

A recent Senate committee hearing on Bill S-17, Parliament's effort to comply with
international trade rules by extending pharmaceutical patent protection to 20 years …

In March, the WTO upheld the" early working provisions" of the Canadian Patent Act that
allow generic manufacturers to seek regulatory approval and develop copies of brand name …

Oxfam Canada is calling on Ottawa to oppose any provisions in a new trade agreement that
would increase patent protection for major pharmaceutical companies and restrict access to …

It is often believed that Canada is in a delicate position as regards adopting a strongly
different patent policy from the United States. It is true that the Canadian economy is still …

The notice must also include either a declaration that the product is not patented in the
destination country or, if it is patented there, a written statement from the country that it has …

This Article takes a close look at Canada's pharmaceutical patent regime. We will examine
the Canadian government's attempts to find a balance between effective patent protection …

Before breaking for the summer, the House of Commons Standing Committee on Industry,
Science, and Technology considered weakening the patent regulations that support Canada …